|
1
|
Knaul FM, Bhadelia A, Gralow J, et al:
Meeting the emerging challenge of breast and cervical cancer in
low- and middle-income countries. Int J Gynaecol Obstet. 119(Suppl
1): S85–S88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harbeck N: American Society of Clinical
Oncology highlights 2013: breast cancer and gynecological
malignancies. Future Oncol. 9:1433–1436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karaoz B, Aksu H and Küçük M: A
qualitative study of the information needs of premenopausal women
with breast cancer in terms of contraception, sexuality, early
menopause, and fertility. Int J Gynaecol Obstet. 109:118–120. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kattan J and Kourie HR: The use of
everolimus to reverse tamoxifen resistance in men with metastatic
breast cancer: a case report. Invest New Drugs. 32:1046–1047. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yaacob NS, Kamal NN and Norazmi MN:
Synergistic anticancer effects of a bioactive subfraction of
Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human
breast cancer cell lines. BMC Complement Altern Med. 14:2522014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alcazar-González GA, Calderón-Garcidueñas
AL, Garza-Rodríguez ML, et al: Comparative study of polymorphism
frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in
Mexican and Spanish women with breast cancer. Pharmacogenomics.
14:1583–1592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hsiang B, Zhu Y, Wang Z, et al: A novel
human hepatic organic anion transporting polypeptide (OATP2).
Identification of a liver-specific human organic anion transporting
polypeptide and identification of rat and human
hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol
Chem. 274:37161–37168. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niemi M, Schaeffeler E, Lang T, et al:
High plasma pravastatin concentrations are associated with single
nucleotide polymorphisms and haplotypes of organic anion
transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics.
14:429–440. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mwinyi J, Johne A, Bauer S, et al:
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b
haplotypes on pravastatin kinetics. Clin Pharmacol Ther.
75:415–421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niemi M, Neuvonen PJ, Hofmann U, et al:
Acute effects of pravastatin on cholesterol synthesis are
associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenet Genomics. 15:303–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Igel M, Arnold KA, Niemi M, et al: Impact
of the SLCO1B1 polymorphism on the pharmacokinetics and
lipid-lowering efficacy of multiple-dose pravastatin. Clin
Pharmacol Ther. 79:419–426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung JY, Cho JY, Yu KS, et al: Effect of
OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of
pitavastatin in healthy volunteers. Clin Pharmacol Ther.
78:342–350. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ieiri I, Suwannakul S, Maeda K, et al:
SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux
transporter) variant alleles and pharmacokinetics of pitavastatin
in healthy volunteers. Clin Pharmacol Ther. 82:541–547. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ozhan G, Kara M, Sari FM, et al: Influence
of the functional polymorphisms in the organic anion transporting
polypeptide 1B1 in the susceptibility to colorectal cancer. Genet
Test Mol Biomarkers. 17:214–218. 2013. View Article : Google Scholar
|
|
15
|
D’Avolio A, Carcieri C, Cusato J, et al:
Intracellular accumulation of atazanavir/ritonavir according to
plasma concentrations and OATP1B1, ABCB1 and PXR genetic
polymorphisms. J Antimicrob Chemother. 69:3061–3066. 2014.
View Article : Google Scholar
|
|
16
|
Hua WJ, Hua WX, Nan FY, et al: The
influence of herbal medicine ursolic acid on the uptake of
rosuvastatin mediated by OATP1B1*1a and *5. Eur J Drug Metab
Pharmacokinet. 39:221–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rose RH, Neuhoff S, Abduljalil K, et al:
Application of a physiologically based pharmacokinetic model to
predict OATP1B1-related variability in pharmacodynamics of
rosuvastatin. CPT Pharmacometrics Syst Pharmacol. 3:e1242014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rohrbacher M, Kirchhof A, Skarke C, et al:
Rapid identification of three functionally relevant polymorphisms
in the OATP1B1 transporter gene using Pyrosequencing™.
Pharmacogenomics. 7:167–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishizato Y, Ieiri I, Suzuki H, et al:
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:
consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther.
73:554–565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jindal C, Kumar S, Choudhari G, et al:
Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene
polymorphism (388A>G) & susceptibility in gallstone disease.
Indian J Med Res. 129:170–175. 2009.PubMed/NCBI
|
|
21
|
Giannakopoulou E, Ragia G, Kolovou V, et
al: No impact of SLCO1B1 521T>C, 388A>G and 411G>A
polymorphisms on response to statin therapy in the Greek
population. Mol Biol Rep. 41:4631–4638. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nozawa T, Nakajima M, Tamai I, et al:
Genetic polymorphisms of human organic anion transporters OATP-C
(SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese
population and functional analysis. J Pharmacol Exp Ther.
302:804–813. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwai M, Suzuki H, Ieiri I, et al:
Functional analysis of single nucleotide polymorphisms of hepatic
organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics.
14:749–757. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sirachainan E, Jaruhathai S, Trachu N, et
al: CYP2D6 polymorphisms influence the efficacy of adjuvant
tamoxifen in Thai breast cancer patients. Pharmgenomics Pers Med.
5:149–153. 2012.PubMed/NCBI
|
|
25
|
Okishiro M, Taguchi T, Jin Kim S, et al:
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not
associated with prognosis, endometrial thickness, or bone mineral
density in Japanese breast cancer patients treated with adjuvant
tamoxifen. Cancer. 115:952–961. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tirona RG, Leake BF, Merino G and Kim RB:
Polymorphisms in OATP-C: identification of multiple allelic
variants associated with altered transport activity among European-
and African-Americans. J Biol Chem. 276:35669–35675. 2001.
View Article : Google Scholar : PubMed/NCBI
|
